T 0036/23 (Production of oligonucleotides/GSK) of 01.04.2025
- European Case Law Identifier
- ECLI:EP:BA:2025:T003623.20250401
- Date of decision
- 1 April 2025
- Case number
- T 0036/23
- Petition for review of
- -
- Application number
- 17739936.7
- IPC class
- C07H 1/00C07H 21/00C12N 9/00
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Novel processes for the production of oligonucleotides
- Applicant name
- GlaxoSmithKline Intellectual Property Development Limited
- Opponent name
- JG Oppositions Limited
Janssen Pharmaceutica N.V. - Board
- 3.3.08
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 100(b)European Patent Convention Art 83Rules of procedure of the Boards of Appeal 2020 Art 012(2)Rules of procedure of the Boards of Appeal 2020 Art 012(3)Rules of procedure of the Boards of Appeal 2020 Art 012(4)Rules of procedure of the Boards of Appeal 2020 Art 012(5)Rules of procedure of the Boards of Appeal 2020 Art 012(6)
- Keywords
- Sufficiency of disclosure - (no)
Sufficiency of disclosure - undue burden (yes)
Amendment to case - reasons for submitting amendment in appeal proceedings (no)
Late-filed evidence - should have been submitted in first-instance proceedings (yes)
Late-filed evidence - circumstances of appeal case justify admittance (no)
Statement of grounds of appeal - party's complete appeal case
Statement of grounds of appeal - reasons set out clearly and concisely (no)
Discretion not to admit submission - requirements of Art. 12(3) RPBA 2020 met (no) - Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is revoked.